Response to "A case of 5-FU-related severe toxicity associated with the P.Y186C DPYD variant"

Clin Pharmacol Ther. 2014 Feb;95(2):137. doi: 10.1038/clpt.2013.207. Epub 2013 Oct 9.

Authors

S M Offer¹, R B Diasio²

Affiliations

¹ Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
² 1] Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA [2] Mayo Clinic Cancer Center, Rochester, Minnesota, USA.

No abstract available

Publication types

Letter
Comment

MeSH terms

Antimetabolites, Antineoplastic / therapeutic use*
Black or African American / genetics*
Dihydrouracil Dehydrogenase (NADP) / genetics*
Female
Fluorouracil / therapeutic use*
Humans
Male
Neoplasms / drug therapy*

Substances

Antimetabolites, Antineoplastic
Dihydrouracil Dehydrogenase (NADP)
Fluorouracil

Grants and funding

P30 CA015083/CA/NCI NIH HHS/United States